125 related articles for article (PubMed ID: 12089219)
1. Boosting bioavailability of topotecan: what do we gain?
Hudes G
J Clin Oncol; 2002 Jul; 20(13):2918-9. PubMed ID: 12089219
[No Abstract] [Full Text] [Related]
2. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Kruijtzer CM; Beijnen JH; Rosing H; ten Bokkel Huinink WW; Schot M; Jewell RC; Paul EM; Schellens JH
J Clin Oncol; 2002 Jul; 20(13):2943-50. PubMed ID: 12089223
[TBL] [Abstract][Full Text] [Related]
3. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
[TBL] [Abstract][Full Text] [Related]
4. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
Drug Metab Dispos; 2007 Jul; 35(7):1142-8. PubMed ID: 17446265
[TBL] [Abstract][Full Text] [Related]
5. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Zhang S; Wang X; Sagawa K; Morris ME
Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.
Yamasaki T; Fujinaga M; Kawamura K; Hatori A; Yui J; Nengaki N; Ogawa M; Yoshida Y; Wakizaka H; Yanamoto K; Fukumura T; Zhang MR
Nucl Med Biol; 2011 Jul; 38(5):707-14. PubMed ID: 21718946
[TBL] [Abstract][Full Text] [Related]
7. Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia.
Burcu M; O'Loughlin KL; Ford LA; Baer MR
Leukemia; 2008 Nov; 22(11):2110-5. PubMed ID: 18418409
[No Abstract] [Full Text] [Related]
8. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.
Breedveld P; Beijnen JH; Schellens JH
Trends Pharmacol Sci; 2006 Jan; 27(1):17-24. PubMed ID: 16337012
[TBL] [Abstract][Full Text] [Related]
9. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
Maliepaard M; van Gastelen MA; Tohgo A; Hausheer FH; van Waardenburg RC; de Jong LA; Pluim D; Beijnen JH; Schellens JH
Clin Cancer Res; 2001 Apr; 7(4):935-41. PubMed ID: 11309344
[TBL] [Abstract][Full Text] [Related]
10. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients.
Kuppens IE; Witteveen EO; Jewell RC; Radema SA; Paul EM; Mangum SG; Beijnen JH; Voest EE; Schellens JH
Clin Cancer Res; 2007 Jun; 13(11):3276-85. PubMed ID: 17545533
[TBL] [Abstract][Full Text] [Related]
11. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.
Allen JD; Jackson SC; Schinkel AH
Cancer Res; 2002 Apr; 62(8):2294-9. PubMed ID: 11956086
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
Leggas M; Panetta JC; Zhuang Y; Schuetz JD; Johnston B; Bai F; Sorrentino B; Zhou S; Houghton PJ; Stewart CF
Cancer Res; 2006 May; 66(9):4802-7. PubMed ID: 16651435
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
14. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
[TBL] [Abstract][Full Text] [Related]
15. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Mol Pharm; 2012 Nov; 9(11):3236-45. PubMed ID: 23020847
[TBL] [Abstract][Full Text] [Related]
16. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
[TBL] [Abstract][Full Text] [Related]
17. Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
van Hattum AH; Hoogsteen IJ; Schlüper HM; Maliepaard M; Scheffer GL; Scheper RJ; Kohlhagen G; Pommier Y; Pinedo HM; Boven E
Br J Cancer; 2002 Sep; 87(6):665-72. PubMed ID: 12237778
[TBL] [Abstract][Full Text] [Related]
18. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Schellens JH; Maliepaard M; Scheper RJ; Scheffer GL; Jonker JW; Smit JW; Beijnen JH; Schinkel AH
Ann N Y Acad Sci; 2000; 922():188-94. PubMed ID: 11193894
[TBL] [Abstract][Full Text] [Related]
19. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
Poller B; Wagenaar E; Tang SC; Schinkel AH
Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
[TBL] [Abstract][Full Text] [Related]
20. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
